Skip to content
Axcess News – Lifestyle
Author:
Capwell Communications
JASMINE Trial Demonstrates Prolacta’s Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan’s Renowned Low NEC Rate
April 30, 2026
Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence
March 7, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
March 5, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
March 4, 2026